Skip to main content
GileadIn development

Gilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion gradually

Source: Autobound Signal API · 68 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

Gilead reported positive Phase 2 clinical trial results for its investigational oral emvistegrast treatment for ulcerative colitis and plans to launch a Phase 3 study in 2027.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Gilead Sciences stock (ISIN US3755581036) was trading at EUR 137.34 at Lang & Schwarz on October 20, 2026, 0.10 percent below the Xetra close of October 19, 2026 at EUR 137.48. On October 19, 2026, Gilead reported positive Phase 2 results for its oral emvistegrast treatment in ulcerative colitis, according to Gilead Sciences . On August 4, 2026, second-quarter total product sales reached USD 7.60 billion, up 8 percent year over year, according to the Yahoo Finance transcript. On October 15, 2026, Gilead announced that third-quarter results and guidance would be released on October 29, 2026. The company then reported the emvistegrast response data on October 19, 2026, making the inflammation pipeline the latest quantified catalyst. The trial enrolled 238 adults and tested three doses against placebo. At Week 12, the 200 mg dose produced a 66 percent clinical response rate versus 37 percent for placebo, while clinical remission reached 31 percent versus 8 percent, according to Reuters. The study remains ongoing, and Gilead plans to initiate a Phase 3 monotherapy study in 2027. The result gives Gilead an oral candidate in a validated inflammatory bowel disease pathway, but it remains an investigational program. The company said adverse events occurred in 36 percent of emvistegrast-treated participants and 37 percent of placebo participants, while the study release cautioned...

Keep reading with a free account

The rest of this article, and every signal for Gilead, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
emvistegrast
Takes effect
Oct 19, 2026

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 20, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/7c50c3d9-70b1-c687-bc50-ec987f7ae5d4 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "7c50c3d9-70b1-c687-bc50-ec987f7ae5d4",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-20T09:16:04+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/gilead-reports-trial-success-gilead-sciences-stock-is-valued-at-usd-189-8-billion-gradually/70371447",
    "title": "Gilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion gradually - ad-hoc-news.de",
    "excerpt": "Gilead Sciences stock (ISIN US3755581036) was trading at EUR 137.34 at Lang & Schwarz on October 20, 2026, 0.10 percent below the Xetra close of October 19, 2026 at EUR 137.48. On October 19, 2026, Gilead reported positive Phase 2 results for its oral emvistegrast treatment in ulcerative colitis, according to Gilead Sciences . On August 4, 2026, second-quarter total product sales reached USD 7.60 billion, up 8 percent year over year, according to the Yahoo Finance transcript. On October 15, 2026, Gilead announced that third-quarter results and guidance would be released on October 29, 2026. The company then reported the emvistegrast response data on October 19, 2026, making the inflammation pipeline the latest quantified catalyst. The trial enrolled 238 adults and tested three doses against placebo. At Week 12, the 200 mg dose produced a 66 percent clinical response rate versus 37 percent for placebo, while clinical remission reached 31 percent versus 8 percent, according to Reuters . The study remains ongoing, and Gilead plans to initiate a Phase 3 monotherapy study in 2027. The result gives Gilead an oral candidate in a validated inflammatory bowel disease pathway, but it remains an investigational program. The company said adverse events occurred in 36 percent of emvistegrast-treated participants and 37 percent of placebo participants, while the study release cautioned that...",
    "product": "emvistegrast",
    "summary": "Gilead reported positive Phase 2 clinical trial results for its investigational oral emvistegrast treatment for ulcerative colitis and plans to launch a Phase 3 study in 2027.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2699366_1920_1080.webp",
    "confidence": 0.95,
    "product_data": {
      "name": "emvistegrast",
      "full_text": "oral emvistegrast treatment in ulcerative colitis",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-20T09:16:04Z",
    "effective_date": "2026-10-19",
    "article_sentence": "On October 19, 2026, Gilead reported positive Phase 2 results for its oral emvistegrast treatment in ulcerative colitis, according to Gilead Sciences ."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.